Psychedelic Use Is Associated With Reduced Daily Opioid Use Among People Who Use Illicit Drugs in a Canadian Setting

Date created
2022-02-01
Authors/Contributors
Abstract
BackgroundResearch into the therapeutic and naturalistic uses of psychedelics for improving outcomes related to mental health disorders has generated increasing interest in recent years. While controlled clinical trials of psychedelics have signaled benefits for treating substance use disorders, this area has not been well studied in the context of naturalistic psychedelic use. This study sought to investigate the possible relationship between recent naturalistic psychedelic use and subsequent daily illicit opioid use among people who use drugs (PWUD). MethodsData (2006–2018) were drawn from three harmonized prospective cohorts of community-recruited PWUD in Vancouver, Canada. We used multivariable generalized linear mixed-effects modeling (GLMM) to estimate the independent association between psychedelic use and subsequent daily illicit opioid use.ResultsAmong 3813 PWUD at baseline, 1093 (29%) reported daily use of illicit opioids and 229 (6%) reported psychedelic use in the past six months. Over study follow-up after adjusting for a range of potential confounders, psychedelic use remained independently associated with a significantly reduced odds of subsequent daily opioid use (Adjusted Odds Ratio: 0.45; 95% Confidence Interval: 0.29 to 0.70).ConclusionWhile confirmation in other settings is required, these findings align with growing evidence that psychedelic use may be associated with detectable reductions in subsequent substance use including illicit opioid use.
Description
The full text of this paper will be available in February, 2023 due to the embargo policies of International Journal of Drug Policy. Contact summit@sfu.ca to enquire if the full text of the accepted manuscript can be made available to you.
Scholarly level
Peer reviewed?
Yes
Language
Member of collection